Kura Oncology’s (KURA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Kura Oncology (NASDAQ:KURAGet Rating)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Kura Oncology’s FY2022 earnings at ($2.21) EPS and FY2023 earnings at ($2.63) EPS.

Other research analysts have also issued research reports about the stock. Credit Suisse Group upped their price objective on shares of Kura Oncology from $27.00 to $29.00 and gave the company an “outperform” rating in a research note on Wednesday, July 13th. Wedbush reiterated an “outperform” rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $37.50.

Kura Oncology Price Performance

KURA stock opened at $12.51 on Wednesday. Kura Oncology has a 12 month low of $10.41 and a 12 month high of $21.10. The firm has a market cap of $836.79 million, a PE ratio of -6.26 and a beta of 0.93. The firm has a 50 day simple moving average of $15.13 and a 200 day simple moving average of $15.17.

Kura Oncology (NASDAQ:KURAGet Rating) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). As a group, sell-side analysts expect that Kura Oncology will post -2.18 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KURA. Nisa Investment Advisors LLC boosted its stake in Kura Oncology by 203.3% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,820 shares of the company’s stock worth $29,000 after acquiring an additional 1,220 shares during the last quarter. Ensign Peak Advisors Inc bought a new position in Kura Oncology in the fourth quarter valued at approximately $82,000. Prospera Financial Services Inc bought a new position in Kura Oncology in the first quarter valued at approximately $86,000. Denali Advisors LLC lifted its stake in Kura Oncology by 71.1% in the second quarter. Denali Advisors LLC now owns 6,500 shares of the company’s stock valued at $119,000 after buying an additional 2,700 shares in the last quarter. Finally, Amalgamated Bank bought a new position in Kura Oncology in the first quarter valued at approximately $123,000.

About Kura Oncology

(Get Rating)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.

Recommended Stories

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.